Field Medical Presents Late Breaking Field PULSE Trial Data at AF Symposium 2026 http://dlvr.it/TQnrH5
Loading...
seen from Malaysia
seen from Singapore
seen from Switzerland
seen from Costa Rica
seen from Netherlands
seen from United States
seen from Philippines
seen from United States
seen from United States
seen from Philippines
seen from United States
seen from United States
seen from United States
seen from Malaysia
seen from Türkiye
seen from China
seen from United Kingdom
seen from United States
seen from China
seen from United States
Field Medical Presents Late Breaking Field PULSE Trial Data at AF Symposium 2026 http://dlvr.it/TQnrH5
Anya is live and ready to show you everything. Watch her strip, dance, and perform exclusive shows just for you. Interact in real-time and make your fantasies come true.
Free to watch • No registration required • HD streaming
Pulsed Field Ablation System: 82% Freedom from VT/VF Recurrence and 98% Reduction in Burden Findings presented at the International VT Symposium and published simultaneously in Circulation. CARDIFF-BY-THE-SEA, Calif. and PHILADELPHIA, Oct. 11, 2025 /PRNewswire/ — Field Medical, Inc. today announced that Circulation has published six-month outcomes from the Ventricular Catheter Ablation Study (VCAS), the first-in-human […] The post Circulation Publishes 6-Month Outcomes from First-in-Human VCAS Trial of FieldForce™ first appeared on AsiaNewsToday.
Pulsed Field Ablation Market Valuation: Where Are We Headed?
The global pulsed field ablation market size was estimated at USD 913.1 million in 2024 and is projected to grow at a CAGR of 33.1% from 2025 to 2030. This is driven by its promise as a safer and more effective alternative to traditional thermal ablation methods. As the global prevalence of atrial fibrillation (AF) rises, there is an increasing demand for innovative treatment options that offer fewer complications and improved outcomes. pulsed field ablation (PFA) non-thermal mechanism significantly reduces the risk of damaging surrounding tissues, a major limitation of conventional ablation techniques like radiofrequency and cryoablation. This unique advantage has led to growing interest from healthcare providers and patients, accelerating its adoption in clinical settings.
Market Concentration & Characteristics
The degree of innovation in the pulsed field ablation industry is high. Cutting-edge developments in catheter technology, energy delivery precision, and real-time monitoring have revolutionized PFA, offering significant improvements over traditional ablation methods. This high innovation level is driving rapid adoption and growth in the cardiac treatment landscape. In October 2024, Abbott received FDA approval for the Advisor HD Grid X Mapping Catheter. This clearance will enhance the mapping process in both pulsed field and radiofrequency ablation procedures, among others. It is expected to improve patient outcomes by providing better visualization of cardiac anatomy during these critical interventions.
The level of M&A activities in the industry is high. Major medical device companies are actively acquiring innovative startups and technology leaders to strengthen their portfolios and capitalize on the growing demand for advanced cardiac arrhythmia treatments. For instance, in June 2024, Boston Scientific Corporation revealed a conclusive agreement to purchase Silk Road Medical, Inc., which specializes in preventing strokes through transcarotid artery revascularization techniques. The acquisition is worth USD 1.16 billion, with each share priced at USD 27.50.
For More Details or Sample Copy please visit link @: Pulsed Field Ablation Market
Key Pulsed Field Ablation Company Insights
The competitive scenario in the industry is high, with key players holding significant positions. The major companies are undertaking various strategies such as new product development, collaborations, acquisitions, mergers, and regional expansion to serve the unmet needs of their customers.